A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Pfizer
Novartis
Takeda
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis
Novartis